Compare DexCom, Inc. (DXCM) vs Western Union Co (WU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Western Union Co — how do they compare? DexCom, Inc. trades at $84.14 (market cap $31.86B), while Western Union Co trades at $6.15 (market cap $1.97B). The key difference: DexCom, Inc. is far larger — about 16.2× Western Union Co's market cap, and Western Union Co pays a 14.85% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Western Union Co for 96 Days on average.
| DXCM | WU | |
|---|---|---|
Market Cap | $31.86B | $1.97B |
Volume | 3,607,070 | 10,235,212 |
Sector | Health | Financials |
52-Week High | $92.34 | $10.28 |
52-Week Low | $54.84 | $5.90 |
Typical Hold Time | 62 Days | 96 Days |
Enterprise Value | $31.32B | $1.88B |
Dividend Yield | — | 14.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
Western Union (WU) trades at $6.12, showing minimal daily movement with a 0.16% gain. The stock demonstrates strong profitability with a 43.97% ROE and attractive valuation metrics including a 5.1 P/E ratio. Recent earnings have been mixed with two misses in the last three quarters, while technical indicators show a bullish overall signal despite bearish moving averages. The company's $200 million efficiency plan and Intermex acquisition represent significant strategic initiatives.
WU presents a value opportunity with deep discount valuation, but faces earnings volatility and competitive pressures. The 12.24% analyst buy rating reflects cautious optimism, with the $6.86 consensus target offering 12% upside. Key risks include integration challenges from acquisitions and margin pressure from digital transformation costs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Western Union Co
Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →
